Skip to content. | Skip to navigation

Garvan Institute

Sections
 

Bone Genetics and Epidemiology

 

Group Leader
Professor John Eisman AO

 
Group Leader
Professor Tuan Nguyen

 
Group Leader
Associate Professor Jackie Center

 

Our research draws on the Dubbo Osteoporosis Epidemiology Study (DOES), which began in 1989 and is the world’s longest running large-scale epidemiological study of osteoporotic fractures in men and women.

We are using the DOES data to develop predictive models, based on multiple risk factors, to identify men and women at high risk of bone fractures and to determine who would benefit most from preventative interventions.

We are also continuing to search for new osteoporosis genes that may predict those who are at low risk of osteoporosis and bone fractures – taking into account environmental factors such as physical activity, dietary habits, medication, fall-related and hormonal factors.

Finding and understanding how these genes work and interact with other known genes will help identify targets for novel therapies.

Staff

Clinical Research Associate
Janet Watters


Ashley DouglasClinical Research Nurse
Ashley Douglas


Nguyen NguyenResearch Officer
Dr Nguyen Nguyen
Heather GordonResearch Assistant
Heather Gordon
Dana BluicResearch Officer
Dana Bliuc
Bich TranPhD Student
Bich Tran
m_chan90.jpgPhD Student
Mei Chan
Malgorzata BrzozowskaPhD Student
Dr Malgorzata Brzozowska
Sing NguyenPhD Student
Sing Nguyen
Shuman YangPhD Student
Shuman Yang

News

 

How a snapshot of ASEAN scientific capabilities can guide us

MEDIA RELEASE: 05 Jul 2011
In the first study of its kind done on the ASEAN countries as a group, a Garvan researcher and Vietnamese colleague have provided a useful snapshot of the scientific landscapes and capabilities of our regional neighbours, and how those attributes are likely to drive their economies.
 
 

An extra 5 years of life an unexpected benefit of osteoporosis treatment

MEDIA RELEASE: 03 Feb 2011
Clinical researchers at Garvan have noted an extraordinary and unexpected benefit of osteoporosis treatment – that people taking bisphosphonates are not only surviving well, better than people without osteoporosis, they appear to be gaining an extra five years of life.
 
 

Beta-blocker use protects bone health

MEDIA RELEASE: 09 Nov 2010
Beta-blocker use increases bone density and reduces risk of osteoporotic fracture by around 50% in men and women, say researchers at Garvan, who used data collected from the long-running Dubbo Osteoporosis Epidemiology Study to demonstrate their findings.
 
 

Personal tools